Molecular effects of stromal-selective targeting by uPAR-retargeted oncolytic virus in breast cancer

Yuqi Jing, Valery Chavez, Yuguang Ban, Nicolas Acquavella, Doraya El-Ashry, Alexey Pronin, Xi Chen, Jaime R. Merchan

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


The tumor microenvironment (TME) is a relevant target for novel biological therapies. MV-m-uPA and MV-h-uPA are fully retargeted, species-specific, oncolytic measles viruses (MV) directed against murine or human urokinase receptor (PLAUR/uPAR), expressed in tumor and stromal cells. The effects of stromal-selective targeting by uPAR-retargeted MVs were investigated. In vitro infection, virus-induced GFP expression, and cytotoxicity by MV-h-uPA and MV-m-uPA were demonstrated in human and murine cancer cells and cancer-associated fibroblasts in a species-specific manner. In a murine fibroblast/human breast cancer 3D coculture model, selective fibroblast targeting by MV-m-uPA inhibited breast cancer cell growth. Systemic administration of murine-specific MV-m-uPA in mice bearing human MDA-MB-231 xenografts was associated with a significant delay in tumor progression and improved survival compared with controls. Experiments comparing tumor (MV-h-uPA) versus stromal (MV-m-uPA) versus combined virus targeting showed that tumor and stromal targeting was associated with improved tumor control over the other groups. Correlative studies confirmed in vivo viral targeting of tumor stroma by MV-m-uPA, increased apoptosis, and virus-induced differential regulation of murine stromal genes associated with inflammatory, angiogenesis, and survival pathways, as well as indirect regulation of human cancer pathways, indicating viral-induced modulation of tumor–stroma interactions. These data demonstrate the feasibility of stromal-selective targeting by an oncolytic MV, virus-induced modulation of tumor–stroma pathways, and subsequent tumor growth delay. These findings further validate the critical role of stromal uPAR in cancer progression and the potential of oncolytic viruses as antistromal agents.

Original languageEnglish (US)
Pages (from-to)1410-1420
Number of pages11
JournalMolecular Cancer Research
Issue number10
StatePublished - Oct 1 2017

Bibliographical note

Funding Information:
This work was supported by a research grant from the NCI (1R01CA149659-01; to J.R. Merchan) and by the Sylvester Comprehensive Cancer Center (J.R. Merchan).

Publisher Copyright:
©2017 AACR.


Dive into the research topics of 'Molecular effects of stromal-selective targeting by uPAR-retargeted oncolytic virus in breast cancer'. Together they form a unique fingerprint.

Cite this